EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Open Access · CC BY 4.0

Five-year follow-up of phase II trial of autologous cord blood mononuclear cells for bronchopulmonary dysplasia prevention in very preterm infants

Zhuxiao Ren iD, Jiangxue Han, Qi Zhang, Wei Wei, Yongsheng Li, Shumei Yang, Fang Xu, Chuan Nie

Stem Cells Translational Medicine · 20.07.2026 · 15 (8)

DOI: 10.1093/stcltm/szag045 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Stem Cells Translational Medicine, online erschienen am 28.07.2026. Verfasst von Zhuxiao Ren und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neonatology, Guangdong Women and Children Hospital, Guangdong Provincial Quality Control Center for Neonatal Intensive Care Medicine, S…. Hauptthemen laut MEDLINE: Bronchopulmonary Dysplasia, Leukocytes, Mononuclear, Fetal Blood. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Guangdong Natural Scientific, Guangzhou Science Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We previously performed a phase II clinical trial involving the intravenous infusion of autologous cord blood mononuclear cells (ACBMNCs) to prevent bronchopulmonary dysplasia in premature infants. We reported the outcomes before discharge and at 2-year follow-up of the enrolled infants. We have reported the developmental outcomes at the 5-year follow-up visit.

Methods

We evaluated the 5-year long-term outcomes of ACBMNCs infusion, including growth, respiratory, and neurodevelopmental outcomes, by interviewing the parents. Children’s development was assessed using scores on the Chinese version of the Ages & Stages Questionnaires (ASQ), third edition (ASQ-3), completed by the parents or guardians. The primary outcome was the neurodevelopmental outcome. The secondary outcomes were growth and respiratory outcomes.

Results

In terms of the primary endpoint, intravenously infused ACBMNCs significantly improved the scores of the fine motor and personal-social domains in the ASQ (P = .044 and P = .048, respectively). This study also showed high consistency between the motor index in the Bayley score at a 2-year follow-up with both gross and fine motor domain scores, as well as the language index with communication, problem-solving, and personal-social domain scores. Although pneumonia-related hospitalizations were similar between the two groups, the intervention group showed a lower possibility of nocturnal cough.

Conclusion

Infants who received intravenous ACBMNC infusion had better fine motor and personal-social abilities at 5 years than those in the control group. In addition to providing reassuring safety data, the study suggested longer-term neurodevelopmental benefits of ACBMNC intervention early in the NICU course. Further randomized placebo-controlled trials are essential to confirm these findings.

Trial registration

The trial was prospectively registered at ClinicalTrials.gov (NCT02999373), registered on December 21, 2016.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bronchopulmonary DysplasiaLeukocytes, MononuclearFetal BloodHumansMaleFollow-Up StudiesInfant, NewbornFemaleInfantTransplantation, AutologousTreatment Outcome

Stichwörter der Autor:innen

autologous cord blood mononuclear cellsbronchopulmonary dysplasiafollow-upneurodevelopmentvery preterm neonates

Autor:innen und Institutionen

  • Department of Neonatology, Guangdong Women and Children Hospital, Guangdong Provincial Quality Control Center for Neonatal Intensive Care Medicine, Southern University of Science and Technology, Guangzhou, 511442, China.
  • Department of Ultrasonography, Children's Hospital, Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, 310052, China.
  • Department of Cord blood, Guang Dong Cord Blood Bank, Guangzhou, 511440, China.

ORCID-Profile: Zhuxiao Ren

Förderung

  • Guangdong Natural Scientific
  • Guangzhou Science Program

Zitieren

APA

Ren, Z., Han, J., Zhang, Q., Wei, W., Li, Y., Yang, S., Xu, F., & Nie, C. (2026). Five-year follow-up of phase II trial of autologous cord blood mononuclear cells for bronchopulmonary dysplasia prevention in very preterm infants. Stem Cells Translational Medicine, 15(8). https://doi.org/10.1093/stcltm/szag045

Vancouver

Ren Z, Han J, Zhang Q, Wei W, Li Y, Yang S, et al. Five-year follow-up of phase II trial of autologous cord blood mononuclear cells for bronchopulmonary dysplasia prevention in very preterm infants. Stem Cells Translational Medicine. 2026;15(8). doi:10.1093/stcltm/szag045

BibTeX
@article{Ren2026,
  author = {Ren, Zhuxiao and Han, Jiangxue and Zhang, Qi and Wei, Wei and Li, Yongsheng and Yang, Shumei and Xu, Fang and Nie, Chuan},
  title = {Five-year follow-up of phase II trial of autologous cord blood mononuclear cells for bronchopulmonary dysplasia prevention in very preterm infants},
  journal = {Stem Cells Translational Medicine},
  year = {2026},
  volume = {15},
  number = {8},
  doi = {10.1093/stcltm/szag045}
}
Kostenlos starten →